Claim: platelet-poor plasma and hemolysis QC should gate plasma miRNA interpretation in RA biomarker work

Grounding: the 2026 RA miR-134-5p study links a plasma miRNA signal to anti-TNF non-response, while pre-analytic miRNA studies in plasma/platelet-poor plasma show that hemolysis and platelet contamination can materially shift circulating-miRNA readouts (PubMed 41924283; PMC3676411; PMC7096393). Limitation: this is an analytical claim about sample handling and interpretability, not evidence that miR-134-5p or any single miRNA should be used alone for treatment selection.